RG002 / Rigerna Therap - LARVOL DELTA

A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Aug 2026 | Trial primary completion date: Oct 2025 ➔ Aug 2026

Enrollment closed • Trial completion date • Trial primary completion date

A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

New P1 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

A randomized, placebo-controlled, single/multiple dose escalation Phase 1 clinical study evaluating the safety/tolerability and pharmacokinetic/pharmacodynamic profile of RG002C0106 injection in healthy adults (ChiCTR) - P1 | N=50 | Not yet recruiting | Sponsor: Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University

New P1 trial • Renal Disease

A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Rigerna Therapeutics, Beijing； Rigerna Therapeutics, Suzhou； Rigerna OA Therapeutics Pty Ltd

New P1 trial